CXCR1 and head and neck squamous cell carcinoma: These findings provide a direct rationale for the clinical study of SX-682 or other inhibitors of CXCR1/2 in combination with docetaxel in the second-line treatment of patients with HPV-negative HNSCC who have failed first-line pembrolizumab treatment.